FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2466164902> ?p ?o ?g. }

• W2466164902 endingPage "e13089" @default.
• W2466164902 startingPage "e13089" @default.
• W2466164902 abstract "e13089 Background: S‐1 is an oral fluoropyrimidine that combines tegafur with two modulators, gimeracil and oteracil potassium. This study was designed to evaluate the PK of S-1 components (FT, CDHP, and Oxo) and the metabolites (5-FU, FBAL, CA) after single and multiple doses of S-1 administered to pts with renal impairment. Methods: This phase I study was conducted in 2 parts (PK Phase and Extension Phase). During the PK Phase, pts were stratified into 4 cohorts: Normal (CrCL >80 mL/min); Mild (CrCL of 51 to 80 mL/min); Moderate (CrCL of 30 to 50 mL/min); Severe (CrCL <30 mL/min). S-1 dosing was determined by degree of renal impairment: 20 mg/m2 QD (severe); 20 mg/m2 BID (moderate); 30 mg/m2 BID (mild), and 30 mg/m2 BID (normal) for 14 days followed by a 1‐week off period. 6 pts were enrolled into each cohort. Plasma and urine were collected to measure the concentrations of S-1 components and its metabolites on day -2 through 48 hrs after the first administration of a single dose of S-1, day 7 and 14. Results: There was no DLTs in the normal (n=7) or moderate(n=6) cohorts. One of 6 pts in the mild cohort experienced 4 DLTs: Gr 3 diarrhea, Gr 3 mucosal inflammation, Gr 3 dehydration, and Gr 3 blood creatinine increased. For the single dose 5-FU and CDHP data, there was statistically significant increase in AUC0-inf value for the mild cohort relative to the normal cohort. For the multiple dose 5-FU, CDHP, Oxo, FBAL, CA, and uracil data, there were no statistically significant differences in Cmax or AUC 0-12 values for the mild or moderate cohort relative to the normal cohort. As compared to normal cohort, there was no evidence of increased accumulation of S-1 components or metabolites following multiple-dose administration in mild or moderate cohort. Conclusions: Based on the results from the single dose PK, a dose reduction from 30 mg/m2 BID to 25 mg/m2 BID for pts with mild renal impairment, 20 mg/m2 BID for pts with moderate renal impairment should be considered for S-1 monotherapy. Data on the severe cohort will be presented at the meeting. S-1 was generally well tolerated in this population with normal renal function, and mild or moderate renal impairment." @default.
• W2466164902 created "2016-07-22" @default.
• W2466164902 creator A5008391854 @default.
• W2466164902 creator A5017962612 @default.
• W2466164902 creator A5035997747 @default.
• W2466164902 creator A5039220665 @default.
• W2466164902 creator A5040886856 @default.
• W2466164902 creator A5045441776 @default.
• W2466164902 creator A5057503413 @default.
• W2466164902 creator A5070594128 @default.
• W2466164902 creator A5073676950 @default.
• W2466164902 creator A5077168338 @default.
• W2466164902 creator A5087442497 @default.
• W2466164902 creator A5087488171 @default.
• W2466164902 date "2011-05-20" @default.
• W2466164902 modified "2023-10-17" @default.
• W2466164902 title "A phase I study evaluating the pharmacokinetics of components of S-1 in pts with varying degrees of renal function." @default.
• W2466164902 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e13089" @default.
• W2466164902 hasPublicationYear "2011" @default.
• W2466164902 type Work @default.
• W2466164902 sameAs 2466164902 @default.
• W2466164902 citedByCount "0" @default.
• W2466164902 crossrefType "journal-article" @default.
• W2466164902 hasAuthorship W2466164902A5008391854 @default.
• W2466164902 hasAuthorship W2466164902A5017962612 @default.
• W2466164902 hasAuthorship W2466164902A5035997747 @default.
• W2466164902 hasAuthorship W2466164902A5039220665 @default.
• W2466164902 hasAuthorship W2466164902A5040886856 @default.
• W2466164902 hasAuthorship W2466164902A5045441776 @default.
• W2466164902 hasAuthorship W2466164902A5057503413 @default.
• W2466164902 hasAuthorship W2466164902A5070594128 @default.
• W2466164902 hasAuthorship W2466164902A5073676950 @default.
• W2466164902 hasAuthorship W2466164902A5077168338 @default.
• W2466164902 hasAuthorship W2466164902A5087442497 @default.
• W2466164902 hasAuthorship W2466164902A5087488171 @default.
• W2466164902 hasConcept C112705442 @default.
• W2466164902 hasConcept C121608353 @default.
• W2466164902 hasConcept C126322002 @default.
• W2466164902 hasConcept C126894567 @default.
• W2466164902 hasConcept C159641895 @default.
• W2466164902 hasConcept C2777288759 @default.
• W2466164902 hasConcept C2777299880 @default.
• W2466164902 hasConcept C2780026642 @default.
• W2466164902 hasConcept C2780306776 @default.
• W2466164902 hasConcept C71924100 @default.
• W2466164902 hasConcept C72563966 @default.
• W2466164902 hasConcept C90924648 @default.
• W2466164902 hasConcept C98274493 @default.
• W2466164902 hasConceptScore W2466164902C112705442 @default.
• W2466164902 hasConceptScore W2466164902C121608353 @default.
• W2466164902 hasConceptScore W2466164902C126322002 @default.
• W2466164902 hasConceptScore W2466164902C126894567 @default.
• W2466164902 hasConceptScore W2466164902C159641895 @default.
• W2466164902 hasConceptScore W2466164902C2777288759 @default.
• W2466164902 hasConceptScore W2466164902C2777299880 @default.
• W2466164902 hasConceptScore W2466164902C2780026642 @default.
• W2466164902 hasConceptScore W2466164902C2780306776 @default.
• W2466164902 hasConceptScore W2466164902C71924100 @default.
• W2466164902 hasConceptScore W2466164902C72563966 @default.
• W2466164902 hasConceptScore W2466164902C90924648 @default.
• W2466164902 hasConceptScore W2466164902C98274493 @default.
• W2466164902 hasIssue "15_suppl" @default.
• W2466164902 hasLocation W24661649021 @default.
• W2466164902 hasOpenAccess W2466164902 @default.
• W2466164902 hasPrimaryLocation W24661649021 @default.
• W2466164902 hasRelatedWork W1544023406 @default.
• W2466164902 hasRelatedWork W1967426700 @default.
• W2466164902 hasRelatedWork W1974378936 @default.
• W2466164902 hasRelatedWork W1997384030 @default.
• W2466164902 hasRelatedWork W2046899919 @default.
• W2466164902 hasRelatedWork W2119107859 @default.
• W2466164902 hasRelatedWork W2126574399 @default.
• W2466164902 hasRelatedWork W2361025871 @default.
• W2466164902 hasRelatedWork W2400700397 @default.
• W2466164902 hasRelatedWork W393698729 @default.
• W2466164902 hasVolume "29" @default.
• W2466164902 isParatext "false" @default.
• W2466164902 isRetracted "false" @default.
• W2466164902 magId "2466164902" @default.
• W2466164902 workType "article" @default.